ProCE Banner Activity

Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML

Slideset Download
Conference Coverage
ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen